Clinical Trial Update: Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial of ibrutinib (PCI-32765) in Waldenström's macroglobulinemia completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED | Results posted: 2020-01-21